Suppr超能文献

蛋白质和肽类治疗药物的非共价聚乙二醇化

Noncovalent PEGylation of protein and peptide therapeutics.

作者信息

Andrianov Alexander K

机构信息

Institute of Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.

出版信息

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Sep-Oct;15(5):e1897. doi: 10.1002/wnan.1897. Epub 2023 May 3.

Abstract

Clinical applications of protein therapeutics-an advanced generation of drugs characterized by high biological specificity-are rapidly expanding. However, their development is often impeded by unfavorable pharmacokinetic profiles and largely relies on the use of drug delivery systems to prolong their in vivo half-life and suppress undesirable immunogenicity. Although a commercially established PEGylation technology based on protein conjugation with poly(ethylene glycol) (PEG)-protective steric shield resolves some of the challenges, the search for alternatives continues. Noncovalent PEGylation, which mainly relies on multivalent (cooperative) interactions and high affinity (host-guest) complexes formed between protein and PEG offers a number of potential advantages. Among them are dynamic or reversible protection of the protein with minimal loss of biological activity, drastically lower manufacturing costs, "mix-and-match" formulations approaches, and expanded scope of PEGylation targets. While a great number of innovative chemical approaches have been proposed in recent years, the ability to effectively control the stability of noncovalently assembled protein-PEG complexes under physiological conditions presents a serious challenge for the commercial development of the technology. In an attempt to identify critical factors affecting pharmacological behavior of noncovalently linked complexes, this Review follows a hierarchical analysis of various experimental techniques and resulting supramolecular architectures. The importance of in vivo administration routes, degradation patterns of PEGylating agents, and a multitude of potential exchange reactions with constituents of physiological compartments are highlighted. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

摘要

蛋白质疗法作为一类具有高生物特异性的新一代药物,其临床应用正在迅速扩展。然而,它们的开发常常受到不良药代动力学特征的阻碍,并且在很大程度上依赖于药物递送系统来延长其体内半衰期并抑制不良免疫原性。尽管基于蛋白质与聚乙二醇(PEG)结合的成熟商业化聚乙二醇化技术——保护性空间屏蔽——解决了一些挑战,但对替代方法的探索仍在继续。非共价聚乙二醇化主要依赖于蛋白质与PEG之间形成的多价(协同)相互作用和高亲和力(主客体)复合物,具有许多潜在优势。其中包括对蛋白质进行动态或可逆保护,同时生物活性损失最小、制造成本大幅降低、“混合搭配”的制剂方法以及扩大聚乙二醇化靶点的范围。尽管近年来已经提出了大量创新的化学方法,但在生理条件下有效控制非共价组装的蛋白质-PEG复合物稳定性的能力,对该技术的商业开发提出了严峻挑战。为了确定影响非共价连接复合物药理行为的关键因素,本综述对各种实验技术和由此产生的超分子结构进行了分层分析。强调了体内给药途径、聚乙二醇化剂的降解模式以及与生理区室成分的多种潜在交换反应的重要性。本文分类如下:治疗方法与药物发现>新兴技术;纳米技术在生物学中的应用>生物学中的纳米级系统;治疗方法与药物发现>肿瘤疾病的纳米医学。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验